课题基金 / 基金详情

SYNTHETIC STUDIES ON TUMOR PROMOTERS & INHIBITORS

SYNTHETIC STUDIES ON TUMOR PROMOTERS & INHIBITORS
肿瘤促进剂的综合研究
批准号:
7957353
负责人:
PAUL Anthony WENDER
金额:
$0.07万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2010-05-31

项目摘要

项目成果

PAUL Anthony WENDER的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 该项目有五个具体目标:D.1:gnidimacrin的合成,gnidimacrin是一种基于PKC靶向治疗癌症的有效先导化合物; D.2:开发瑞香烷家族抗癌先导化合物的通用和灵活路线并研究其活性; D.3:瑞香烷-惕各烷杂合物的合成和生物学评价; D.4:laulimalide类似物的合成和生物学评价,对紫杉醇耐药性癌症有活性的化合物; D.5:设计,合成,以及涉及真实的时间生物发光测定的药物和探针转运蛋白的评价基于细胞外蛋白酶的激活。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is directed at five specific aims: D.1: The synthesis of gnidimacrin, a potent lead for the treatment of cancer based on PKC targeting; D.2: The development of a general and flexible rout to anticancer leads in the daphnane family and study of their activity; D.3: The synthesis and biological evaluation of daphnane-tigliane hybrids; D.4: The synthesis and biological evaluation of laulimalide analogs, compounds active against taxol resistant cancers; D.5: The design, synthesis, and evaluation of drug and probe transporters involving a real time bioluminescence assay with a specific focus on transporter conjugates that are designed for selective cell or tissue entry based on activation by extracellular proteases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal
HIV latency reversal through novel, potent PKC modulators
HIV Latency Reversal Through Novel, Potent PKC Modulators
海外基金